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ABSTRACT 
Background 
Hypertension is a common chronic disease, which is expensive to treat 
and has serious but preventable long-term complications. It should be 
possible to optimize antihypertensive therapy such that the most prevention is 
obtained with the least cost. This optimization can be approached through 
adherence to current national evidence-based practice guidelines for the 
treatment of hypertension. 
Objectives 
The objectives of this study are: (1) to test hypotheses regarding 
comorbidities and prescribing in hypertension and, (2) to identify opportunities 
to improve adherence to treatment guidelines for hypertension. 
Methods 
The study employs a nonconcurrent cohort research design for 
hypothesis testing in incident uncomplicated cases of hypertension. The 
practice recommendations from the Joint National Committee on Prevention , 
Detection , Evaluation, and Treatment of High Blood Pressure were translated 
into operational definitions of uncomplicated hypertension , relevant 
comorbidities, and drug class prescribing . Administrative claims data were 
used to classify cases with respect to diseases and classes. These 
classifications were used to test for predicted disease-class associations. 
Results 
Multivariate adjusted odds ratios (OR) and 95% confidence intervals 
(Cl) for significant associations include: Angiotensin Converting Enzyme 
(ACE) inhibitor (5.88 OR, 2.57-13.43 Cl) and diuretic (10.87 OR, 4.70-25.15 
Cl) prescribing positively associated with congestive heart failure ; beta-
blocker (4.39 OR, 2.93-6.56 95% Cl) and calcium channel blocker (CCB) (2.70 
OR, 1.88-3.86) prescribing positively associated with coronary artery disease; 
beta-blocker prescribing negatively associated with chronic obstructive 
pulmonary disease (0.50 OR, 0.33-0.75 Cl) and diabetes mellitus (0.56 OR, 
0.38-0.82 Cl) ; and ACE inhibitor prescribing positively associated with 
diabetes mellitus (1 .73 OR, 1.38-2.16 Cl). Additional significant associations 
were found in bivariate analyses reported as unadjusted relative risks (RR) 
and 95% confidence intervals (Cl) including: a positive association of ACE 
inhibitor prescribing in renal failure (1.84 RR, 1.11-3.04 Cl) and negative 
associations between diuretic (0.69 RR, 0.58-0 .83 Cl) and beta-blocker (0.62 
RR, 0.50-0.77 Cl) prescribing with dyslipidemia. Diuretics and beta-blockers 
(38.8%) are not used more frequently as first line therapy than CCBs and ACE 
inhibitors (59.7%) in uncomplicated hypertension. 
Conclusions 
The predicted associations were largely confirmed, providing evidence 
for appropriate prescribing in hypertension. Analysis of claims data can be a 
useful method of measuring prescribing practices in hypertension. The details 
of this methodology and its limitations are discussed. The major opportunity 
for improvement relates to under-prescribing of diuretics and beta-blockers, 
and over-prescribing of calcium channel blockers and ACE inhibitors in 
uncomplicated hypertension. 
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PREFACE 
This dissertation was prepared in the format of the standard dissertation 
plan . There is one manuscript divided into six sections. These include the 
statement of the problem, introduction, methods, results, discussion, and 
bibliography. Two appendices follow the manuscript. Tables appear at the 
end of the body of the text. 
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MANUSCRIPT 
STATEMENT OF THE PROBLEM 
The purposes of the study are to measure the influence of comorbid 
medical conditions on the prescribing of antihypertensive drug therapeutic 
classes and to identify opportunities for improvement in prescribing. It is 
expected that known indications and contraindications influence the selection 
of pharmaceutical classes for the treatment of hypertension. The magnitude 
of this effect has not been estimated. A large administrative medical claims 
database will provide a useful window into current prescribing practices. This 
study will serve to identify opportunities for improvement in 
pharmacotherapeutic aspects of hypertension management. The results will 
be useful in efforts to improve selection of antihypertensive agents. 
INTRODUCTION 
Hypertension is a common chronic disease in adults with harmful 
consequences that can be prevented with effective therapy. Hypertension is 
treated by lifestyle modification and when necessary, pharmacologic therapy. 
The goal of therapy is to reduce blood pressure without intolerably impairing 
patients' quality of life. Individualization of therapy is important in reaching 
optimal outcomes. Comorbid conditions, demographic variables, economic 
considerations, side effect profiles, and patient preferences should influence 
the individualization of therapy. There can be however, unexplained and even 
undesirable influences on practice variation (Kaplan , 1994; Kaplan , 1998a). 
The details of therapy are important to study because of their associated costs 
and outcomes. It can be estimated that the wholesale costs for the top four 
classes of anti hypertensive agents exceeded $5 billion in 1995 (Siegel and 
Lopez, 1997). Heart disease and stroke are the first and third leading causes 
of death in this country and are both associated with hypertension. The 
financial burden alone for these illnesses has been estimated at over $259 
billion in direct and indirect costs (JNC 6, 1997). For these reasons, 
hypertension is a useful condition to study for the purposes of health care 
quality improvement. 
Health Care Quality Improvement 
The health care delivery system in the United States is going through 
rapid evolutionary change (Drake, 1997). The stimuli for these changes are 
largely economic; however, issues of quality have started taking center stage 
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(President's Advisory Commission on Consumer Protection and Quality in the 
Health Care Industry, 1998). The concepts of Quality and Cost can be 
combined , studied, and understood using the Health Care Value Equation 
(Toscani, 1997): 
Value = Quality/Cost 
It is useful to think about maximizing Value as the goal of our health care 
delivery system. This can be accomplished by increasing Quality while 
holding Cost constant or decreasing Cost while holding Quality constant. 
Critics of managed care might argue that some managed care organizations 
(MCO) are increasing Value by cutting Costs at the expense of smaller 
reductions in Quality. 
The modern practice of Health Care Quality Improvement (Jencks and 
Wilensky, 1992) approaches the equation in a different way. Ideally, the goal 
of health care quality improvement is to maximize Value by both increasing 
Quality and decreasing Cost. This can be accomplished only through 
systematic approaches to performance improvement. These systematic 
approaches require frequent measurement for the purposes of identifying 
opportunities for improvement, root cause analysis, design of interventions, 
and evaluation of the interventions (Melum, 1995). Reliable, objective, low 
cost measurement is essential to this method of performance improvement. 
The models developed in this doctoral dissertation should be useful for 
systematic efforts to measure and improve performance in the treatment of 
hypertension. Such improved performance should increase Value as it relates 
to the treatment of hypertension. 
Hypertension has two sets of costs, those associated with treatment 
and those associated with consequences of the disease. From a health 
economic perspective, optimal Value occurs when we maximize the 
prevention of long-term complications of hypertension while we minimize the 
costs associated with treatment. Costs are relatively easy to quantify; quality 
is more difficult. 
Quality Measurement 
Quality has been defined as "the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes 
and are consistent with current professional knowledge" by the Institute of 
Medicine (Palmer, 1997). Donabedian proposed a framework for measuring 
quality more than 30 years ago that still influences current thinking on these 
issues (Donabedian, 1966). He suggested that data for quality measurement 
should be classified according to the structures, processes, and outcomes of 
care. The outcomes are the results or consequences of disease and health 
services. These outcomes can include changes in health status (morbidity 
and mortality) or more subjective measures (quality of life or functional status) . 
The processes are the health services and other actions used to produce 
outcomes. The structures are the people, places, and things used to deliver 
those services and other actions. Modern quality science has largely moved 
away from the earlier structural measures to those of outcomes and 
processes . For performance improvement purposes, outcomes often take too 
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long to occur and can be due to influences other than the processes under the 
system's control and statistical methods cannot always adjust for these 
confounding influences. Therefore, process measurement has become the 
more common method in quality improvement science. Systematic 
performance improvement approaches focus primarily on processes and the 
IOM definition of quality is primarily process oriented . At the level of 
processes, quality can been more simply defined as doing the right things, and 
doing them well (JCAHO, 1994). 
The right things "increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge." These principles call for 
evidence of known process-outcome relationships with strong evidence bases 
supporting them. In the absence of best evidence, expert consensus opinion 
can suffice. These "right things" are currently defined by practice guidelines 
with varying degrees of evidence supporting their recommendations. These 
principles are also consistent with the growing movement called "Evidence 
Base Medicine." One of the leaders of this movement describes: "Evidence 
based medicine is the conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of individual patients. The 
practice of evidence based medicine means integrating individual clinical 
expertise with the best available external clinical evidence from systematic 
research . .. " (Kaplan, 1998a). 
Peer reviewed literature can supplement the recommendations of 
practice guidelines. Health care quality improvement science uses the 
recommendations of practice guidelines, develops measurable indicators of 
performance, and uses the results of such measurement to identify 
opportunities for improvement. Objective measurement can be used to 
develop interventions to improve performance on a system-wide basis. 
Repeat measurements are used to evaluate the effects of targeted 
interventions. To suit these purposes, measurement should be relatively 
inexpensive and unobtrusive. The measures developed in this study should 
meet those requirements. These measurements should be relatively 
inexpensive because they will be derived from data already collected . 
Expensive chart abstraction can be avoided. These measures should be 
unobtrusive because the data collection occurs retrospectively and there is no 
burden on the practitioners. 
Guidelines 
There are well accepted , evidence based guidelines for the treatment of 
hypertension that are revised by a national panel of experts every four to five 
years. This expert panel, the Joint National Committee on Prevention, 
Detection , Evaluation, and Treatment of High Blood Pressure (JNC 5, 1994; 
JNC 6, 1997) was brought together as part of the National High Blood 
Pressure Education Program (NHBPEP) by the National Heart, Lung , and 
Blood Institute (NHLBI) of the National Institutes of Health (NIH). The 
continuing effort has lasted more than a quarter century. The reports of the 5th 
and 5th committees are used in this study. The recommendations of the 5th 
report were used to create the quality indicators and the study interval (1994-
6 
1995) fell within the period after the 5th and before the 5th reports. The results 
are discussed with respect to the recommendations of both the 5th and 5th 
reports. 
Epidemiology of Hypertension 
Hypertension is the most prevalent disease in this country. affecting 
approximately 50 million adults (28% of the adult population) when estimated 
in 1988-1991 (Burt. Whelton, Roccella et al , 1995). Blood pressure increases 
with age; the prevalence exceeds 50% at ages greater than or equal to 50 
(Margolis and Klag, 1998). Most people will develop hypertension at some 
time during their lives. Hypertension is the second most common reason for 
visits to physicians in this country, more than 100 million annually (Kaplan. 
1998c). Other risk factors for hypertension include race. obesity, diabetes 
mellitus. and family history of hypertension (Burt et al, 1995; Margolis and 
Klag . 1998). 
Impact of Hypertension 
Consequences of hypertension are important in terms of morbidity. 
mortality, and health service costs. Sustained hypertension is associated with 
higher overall mortality rate. stroke, myocardial infarction. and kidney disease 
(Kaplan. 1998d). Morbidities associated with hypertension are expressed as 
end organ damage of the heart. brain, kidneys, eyes, and blood vessels. 
Heart disease associated with hypertension takes two forms, coronary 
artery disease and congestive heart failure. Hypertension contributes toward 
the progression of atherosclerotic disease and increases the workload on the 
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( left ventricle. Atherosclerosis in the coronary arteries causes a decrease in 
blood flow to the heart and can result in tissue ischemia, experienced as 
symptomatic disease (angina), or tissue death (myocardial infarction). The 
increase in workload on the left ventricle causes the heart muscle to 
hypertrophy and eventually to fail (Levy, Larson , Ramachandran et al, 1996). 
The heart is considered to be in failure when it can no longer pump an 
adequate supply of blood to the vital organs. 
The brain is effected by hypertension primarily by two pathophysiologic 
processes, atherosclerotic disease and aneurysmal dilatation (Margolis and 
Klag, 1998; Kaplan (1998d) . Hypertension contributes toward atherosclerotic 
disease of the cerebrovascular system that can result in inadequate blood 
supply to the brain. If the deficiency causes symptoms that are temporary, the 
syndrome is called a transient ischemic attack (TIA) . If the deficiency results 
in brain tissue death, it is called a stroke. Hypertension can cause rupture of a 
cerebral aneurysm resulting in an intracerebral hemorrhage. 
The kidneys are damaged by atherosclerotic disease of the large 
arteries to the kidneys and by disease of the smaller arteries of the kidneys. 
Kidney disease can lead to long term dialysis or kidney transplantation. 
Kidney disease also contributes toward high blood pressure. Vision can be 
impaired when hypertension causes damage to the small vessels of the eyes 
(Kaplan, 1998d). 
Vascular disease secondary to hypertension can take other forms. 
Peripheral vascular disease (PVD) typically involves atherosclerosis of the 
large vessels in the legs. The reduced blood supply can cause symptoms of 
claudication (ischemic leg pain) and can cause tissue death. Treatment of 
PVD often involves bypass surgery. Severe disease can lead to amputation . 
Hypertension can cause weakening in vessel walls that can lead to rupture of 
the vessel. The rupture of a large artery (e.g. aorta) results in a catastrophic 
bleed (Kaplan, 1998d). 
These consequences have costs in terms of human suffering and lost 
productivity; however, these costs are difficult to measure. The costs of the 
health services associated with these consequences are easier to measure. 
These include professional services, hospitalization services, and medications. 
Professional services include physicians and other health care provider 
interventions. Hospitalization services include medical, surgical , and 
rehabilitation interventions. Medications include the drugs used to treat the 
consequences of hypertension. Precise measurement of these costs would 
be important in assessing the overall Value in the treatment of hypertension. 
Since this study focuses on quality, such precise cost estimates are beyond 
the scope of this investigation. Just to place some of these costs in 
perspective, hypertension is the second most common indication for physician 
office visits and cardiovascular drugs are the most commonly prescribed 
category of pharmaceutical agents (Woodwell, 1997). 
Treatment of Hypertension 
Hypertension can be successfully treated. Effective treatment lowers 
risk for end organ damage and mortality (Kannel, 1996) (14). The treatment of 
( hypertension includes lifestyle modification (Kaplan , 1998e) or non-
pharmacologic therapy and the use of drugs when necessary (Kaplan , 1998a). 
The goal of treatment is to lower blood pressure without intolerably impairing 
the quality of life. 
Lifestyle modification includes weight loss for people who are obese, 
dietary change that can include a reduction in salt (TOMHS, 1991). calories 
and alcohol, increasing physical activity and exercise, and smoking cessation 
(Kaplan, 1998e). 
For those patients who cannot lower their blood pressures with lifestyle 
modification alone, pharmacologic therapy is necessary. There are more than 
50 antihypertensive pharmacologic agents. These can be divided into major 
classes. The five major classes include (Kaplan and Gifford , 1996): diuretics, 
beta-blockers, calcium channel blockers (CCB). angiotensin converting 
enzyme inhibitors (ACE inhibitors). and alpha-blockers. The prescription of 
these five classes is the focus of this study. 
Diuretics lower blood pressure by decreasing blood volume through the 
elimination of sodium and water in the kidneys. They have the advantages of 
lower cost and have been demonstrated to reduce long term consequences of 
hypertension (JNC 6). The potential disadvantages include hypokalemia, 
hyponatremia, hypomagnesemia, hyperuricemia, hypercalcemia, 
hyperlipidemia, glucose intolerance/insulin resistance, impotence, and 
orthostasis (Kaplan and Gifford, 1996). 
Beta blockers lower blood pressure by decreasing the heart rate and 
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the force of contraction. They are advantageous for people with known 
coronary artery disease since they have antianginal and antiarrhythmic effects. 
The antianginal effects can reduce symptoms of ischemia. Beta blockers 
prevent sudden death in patients who have had myocardial infarction 
(Hennekens, Albert, Godfried et al , 1996). They have been demonstrated to 
reduce long term consequences of hypertension. Their disadvantages include 
side effects of insomnia, depressed mood, exercise intolerance, impotence, 
and dyslipidemia. They can be particularly harmful to people with comorbid 
congestive heart failure or asthma (Kaplan, 1998a). 
Calcium channel blockers lower blood pressure by relaxing the muscles 
in the arterial walls. They have advantages in their relatively benign side 
effect profiles and can relieve symptoms of angina but have not been 
demonstrated to reduce long term consequences of hypertension. They may 
cause constipation, headaches, flushing, and ankle edema. Some calcium 
channel blockers (those that decrease myocardial contractility) can be harmful 
in congestive heart failure (Kaplan , 1998a). 
Angiotensin converting enzyme inhibitors (ACE inhibitors) prevent the 
formation of angiotensin, which has powerful vasoconstricting properties. This 
mechanism lowers the blood pressure by dilating the blood vessels. These 
agents have the advantages of being well tolerated and are particularly 
beneficial to people with heart failure, renal damage (particularly diabetic 
nephropathy) , and post myocardial infarction. However, they have not been 
demonstrated to reduce the long-term consequences of hypertension alone. 
II 
The most common side effect is a dry cough (Kaplan, 1998a). 
Alpha blockers lower blood pressure by inhibiting vasoconstrictive 
nerve impulses. They have the advantages of a relatively benign side effect 
profile and can reduce symptoms of prostate disease. They have not been 
demonstrated to reduce long term consequences of hypertension. They can 
cause severe orthostasis in the elderly and may cause urinary incontinence in 
women. 
Selection of Antihypertensive Agents 
The treatment of hypertension has been extensively studied and 
periodic evidence-based recommendations are made. The Joint National 
Committee on Prevention, Detection , Evaluation, and Treatment of High Blood 
Pressure (JNC) issues these recommendations every four to five years. The 
recommendations from the last two reports have been used in this study for 
reasons cited above. In summarizing the recommendations pertinent to this 
study the following points must be made: 1) the JNC VI largely upheld the 
recommendations of the JNC V, as they relate to this study; 2) the reports 
recommend that diuretics and beta blockers should be used as first line agents 
because they have been proven to reduce morbidity and mortality; and 3) drug 
therapy should be tailored to the individual needs of patients taking into 
consideration such factors as age, race, comorbid conditions, lifestyle, and 
economic status. The effect of comorbid conditions on the selection of 
hypertensive classes is the primary subject of this study. Some examples 
were alluded to in the description of the five major classes, above. Important 
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comorbid conditions that were selected for this study include: dyslipidemia, 
coronary artery disease, congestive heart failure , diabetes mellitus, renal 
failure , prostatic hypertrophy, and chronic obstructive pulmonary disease. Age 
and gender are potentially important demographic variables that should 
influence class selection (JNC 5, JNC 6, Kaplan , 1998a). 
Despite the recommendations of the JNC it has been demonstrated that 
CCB and ACE inhibitor prescribing are increasing while diuretic and beta-
blocker prescribing are decreasing (Kaplan , 1994, Siegel and Lopez, 1997). 
Until very recently (Mehta, Wilcox, and Schulman, 1999), published studies 
had not been able to associate prescribing with disease states that should 
influence selection of particular classes of agents. This study will address this 
important gap in the literature. 
Therapeutic class associations with comorbidities can be divided into 
three categories: compelling indication for use; may have favorable effect on 
comorbidity; and , may have unfavorable effect on comorbidity (JNC 6). The 
first two categories can be considered preferred agents. The third category 
can be considered less preferred agents. Preferred agents should be 
expected to be used for the treatment of hypertension in patients with the 
given comorbidity or demographic risk factor more often than for the treatment 
of hypertension in patients without the comorbidity or risk factor. Less 
preferred agents should be expected to be used for the treatment of 
hypertension in patients with the given comorbidity or demographic risk factor 
less often than for the treatment of hypertension in patients without the 
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comorbidity or risk factor. The relationships should be strongest where 
compelling indications exist. 
Measurement Methodology 
Administrative claims data have been recommended as an appropriate 
source for pharmacoepidemiologic research and specifically for the purposes 
of measuring health care quality (lezzoni, 1997; Quam et al, 1993). The 
advantages of using this source of data include: 1) data collection costs are 
relatively low since the data are already available in electronic form; 2) studies 
using these data are unobtrusive to providers and patients; 3) the claims 
database can provide a population-based, longitudinal record, across 
treatment sites; and 4) these data are not adversely influenced by patient 
recall biases. The disadvantages include: 1) diagnosis and treatment 
information may be incomplete; 2) the validity of data elements is often not 
well established; and 3) the data were not collected primarily for the purpose 
of study. 
Claims data have been used to identify patients with hypertension and 
the validity of this method of measurement has been studied and compared to 
other methods of identification (Quam et al, 1993). Investigators looked at 3 
methods of claims based identification and compared them with chart review 
and patient survey data. The study population consisted of patients from two 
independent practice association health plans that contracted with 
independent practitioners who billed discounted fee-for-service to the plans. 
The two study years were calendar years 1988 and 1989. For all three 
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methods, patients with specific comorbidities were excluded from analysis. 
The first claims based method focused specifically on diagnosis codes, the 
second utilized pharmacy claims, and the third method used a combination of 
pharmacy and diagnosis data. The diagnosis-based definition required at 
least one claim within a two year time period using any of ICD-9-CM codes 
401 , 401.0 , 401.1 or 401.9 and specifically excluded those with pharmacy 
claims for antihypertensive medications. The pharmacy-based definition 
required at least one prescription for an antihypertensive agent without any 
diagnosis codes (above) for hypertension. These two sets of criteria were 
designed to be mutually exclusive and to identify patients without specific 
comorbidities. The combined definition required both a diagnosis code and a 
claim for an antihypertensive agent. Patients were classified as hypertensive 
by the survey method if they answered positively when asked if a doctor ever 
told them that they have hypertension or high blood pressure. Patients were 
classified as hypertensive by the medical chart review method if they: (1 ) had 
hypertension or a synonym listed as a current or historical problem; (2) they 
had two measured elevated blood pressure readings recorded on the most 
recent office visits; or (3) antihypertensive therapy was listed and there was at 
least one recorded measurement of elevated blood pressure. 
Initial analysis revealed approximately 50% agreement between the diagnosis-
based and prescription-based definitions and both the medical record-based 
and survey-based definitions. The diagnosis-based definition, when modified 
to require two diagnosis codes in the time interval, performed much better, 
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agreeing with medical record-based definition almost 75% of the time. 
The use of administrative medical claims data has been compared with 
a survey methodology in the identification of patients with diabetes mellitus 
and heart disease (O'Connor, Rush , Pronk, and Cherney, 1998). These 
investigators found that 2 codes for diabetes mellitus in a 2-year period yielded 
a sensitivity and specificity of 0.91 and 0.99 respectively with a positive 
predictive value of 0.94. For heart disease these investigators looked for one 
code in a defined one-year period of time. This strategy yielded sensitivity, 
specificity, and positive predictive values of 0.89, 0.99, and 0.85 respectively. 
The heart diseases that were of interest in this study included congestive heart 
failure , history of myocardial infarction, angina, and arteriosclerotic 
cardiovascular disease. It was recognized from previous work that in diabetes 
mellitus, a one code requirement leads to false identification of patients. 
Use of administrative claims data, has typically been used in the in-
patient setting (lezzoni, 1997) but has been increasingly used in the 
ambulatory setting. Pharmaceutical therapy prescribing was studied using a 
similar measurement methodology for ambulatory patients with diabetes 
mellitus (Glauber and Brown, 1992). 
The results of these studies were used to determine the strategy used 
in the current study. It was decided that two codes would operationally define 
hypertension and the relevant comorbidities since false positive rates can be 
high with a one code requirement. It was anticipated that the associated 
decrease in sensitivity and potential decrease in sample size would not be a 
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problem using the large population covered by the database that was acquired 
for this study. 
Hypotheses 
In incident uncomplicated cases of hypertension specific comorbidities 
should influence the prescribing of antihypertensive drug classes. Positive 
associations should be observed between ACE inhibitors and diuretics in 
congestive heart failure and between beta-blockers and CCBs in coronary 
artery disease. ACE inhibitors should be positively associated with diabetes 
mellitus and renal insufficiency, particularly in diabetic nephropathy. Alpha 
blockers should be positively associated with benign prostatic hypertrophy. 
Negative associations should be observed between beta-blockers in chronic 
obstructive pulmonary disease, congestive heart failure , diabetes mellitus, and 
dyslipidemia. Negative associations should be observed for CCBs in 
congestive heart failure and diuretics in dyslipidemia. 
In incident cases of uncomplicated hypertension without relevant 
comorbidities (congestive heart failure, coronary artery disease, chronic 
obstructive pulmonary disease, diabetes mellitus, renal insufficiency, 
dyslipidemia, and benign prostatic hypertrophy) diuretics and beta-blockers 
should be prescribed as first line agents. 
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METHODS 
Research Design 
The study employs a nonconcurrent cohort research design to test 
hypotheses concerning class prescribing in the presence and absence of 
relevant comorbidities. This longitudinal design focuses on prescribing that 
occurs only after the diagnoses of relevant comorbidities have been made. 
Patient Population 
Data for analysis were obtained from the claims database of a large 
Blue Cross and Blue Shield plan through a contract with the nonprofit Hawaii 
Medical Service Association Foundation 1. This plan is the largest provider of 
health care coverage in the state of Hawaii. Of the 1.1 million insured in 
Hawaii this plan covers 53%. Hawaii's population is ethnically diverse. 
Roughly a third of the population is white, over 60% are Asian or Pacific 
Islander. The remaining 5% are split among black, American Indian, and other 
races. Of the Asian or Pacific Islanders, over 22% are Japanese, over 15% 
are Filipino, over 12% are Hawaiian, and over 6% are Chinese. The 
remaining 7.5 % are split among Korean , Vietnamese, Samoan, and other. 
Over 7% of the population living in Hawaii are of Hispanic origin. The health 
system in Hawaii is similar to that of other US states with two important 
exceptions: 1) health care coverage in Hawaii is nearly universal since 
employers are required to provide coverage to all half-time and full-time 
' The HMSA Foundation is a private grantmaking charity affiliated with HMSA. Its primary 
activities include grantmaking, research , education and community service publications. 
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r employees; and 2) there is almost no migration beyond the islands (Hawaii 
Medical Services Association Foundation , 1995). These characteristics make 
this population particularly useful for epidemiological study. Potential cases 
for study included patients in the fee-for-service plan with a diagnosis of 
hypertension at any time during calendar years 1994 through 1996. 
Database 
The Blue Cross and Blue Shield database included three files : the 
pharmacy file , the medical file , and the demographics file. These files were 
linked using an unique patient identification code without revealing the actual 
identity of individuals. 
Pharmacy claims data included individual drug generic names, 
therapeutic class codes, dispense date, supply, and units. Generic names and 
therapeutic class codes from the pharmacy file were used to identify 
therapeutic class utilization. A patient was classified to have used the 
therapeutic class if he/she received an agent from that class at least once 
during the study interval; cases in which the first occurrence of class 
prescribing preceded the first date of diagnosis were eliminated . Medical 
claims data included diagnosis codes, procedure codes, dates of service, 
place of service, provider and specialty identifiers. ICD-9 CM codes (HCFA, 
1994) from the medical claims file were used to determine the presence of 
hypertension and target comorbidities (Table 1). The demographics file 
included birth date, gender, dates in the plan , and type of plan. 
The data were obtained in flat file format, however, the size of the data 
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base required normalization. This was accomplished in Microsoft Access for 
Windows 95 , Version 7.0. Preliminary data cleaning and initial univariate 
analyses were performed using Microsoft Access prior to univariate, bivariate, 
and multivariate statistical analyses being performed using the SAS System 
for Windows, Release 6.11 . Output from SAS analyses were manually 
entered into Microsoft Excel spreadsheets for additional manipulation and 
display. The results of Excel analyses appear in tables in the body of the text. 
Data Cleaning 
Patients without any ICD-9 CM code for hypertension were eliminated. 
Range checks were performed on age, gender, and visit frequency. Non-
sense values on these variables were identified and associated patients 
eliminated from analyses. In addition, a gender by diagnosis search was 
performed to identify any potential erroneous combinations (e.g. women with 
benign prostatic hypertrophy). Those identified (11 cases) were also 
eliminated from analyses. Frequencies of diagnoses over time and 
prescription use over time were used to evaluate for inconsistencies in the 
database. 
Disease Definitions 
Prevalent cases of hypertension and relevant comorbidities were 
operationally defined by the presence of two or more codes from a target set 
of ICD-9 CM codes, specific to hypertension or the relevant comorbidity, in a 
given patient, on two or more visits, within the three calendar years 1994-
1996. These target sets of codes appear in Table 1. Incident cases of 
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( uncomplicated hypertension were operationally defined in the same manner 
with an additional requirement that they have a one-year period free of 
antihypertensive drug therapy prior to the index diagnosis and that they have 
no coded complications of hypertension. The index diagnosis is defined as 
the first appearance of a target diagnostic code within the three calendar 
years. A subset of cases for the incident, uncomplicated cases of 
hypertension were identified who had no defined relevant comorbidities. This 
subset were chosen to look at class prescribing in the groups of patients most 
likely to be following the JNC recommendations for first line therapy in 
uncomplicated hypertension. 
Alternative strategies for operationally defining prevalent cases were 
explored. The effects of these strategies on potential sample sizes are 
summarized in Appendix A. 
Pharmacologic Class Definitions 
A patient was classified as having been prescribed a pharmacologic class if 
there was at least one appearance of a drug from that class in the pharmacy 
file . The first date of fill for an agent in each class was identified. Those dates 
were used to determine the order of class prescribing in the treatment 
regimens. When combination agents were used or two classes were initiated 
on the same date, both classes were assigned that order in the regimen . The 
first date of fill for each class was used to establish the temporal relationship 
between diagnoses of relevant comorbidities and the prescribing of classes 
predicted to be influenced by those diagnoses. In bivariate analyses, cases in 
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which the first occurrence of class prescribing preceded the first date of 
diagnosis were eliminated. The presence of comorbidities and pharmacologic 
classes were coded as one. Their absence was coded as zero. 
Univariate Analyses 
Frequencies were obtained for ICD-9 CM codes, unique patients with 
ICD-9 CM codes, unique patients with specific comorbities, unique patients 
dispensed specific pharmacologic agents, and unique patients dispensed 
pharmacologic classes. A patient was classified as having been dispensed 
the class if there was at least one prescription filled from that class in the 
period of investigation, regardless of when that occurred . 
Bivariate Analyses 
Bivariate analyses were performed using 2 X 2 tables from the FREQ 
procedure in SAS Version 6 (SAS, 1995) to evaluate the associations of the 
relevant comorbities with the dispensing of pharmacologic agents using Chi-
square and Fisher's exact test. In order to ensure that comorbidities were 
known prior to the prescribing decision, only cases in which the relevant 
comorbidities preceded prescribing of the associated classes were included in 
th is set. 
Multivariate Analyses 
Backward elimination logistic regression analyses (SAS, 1995b) were 
performed to evaluate the independent effects of comorbidities and 
demographic risk factors on the dispensing of specific drug classes. The 
models for these logistic regression analyses used diuretic (DI), beta blocker 
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(BB) , calcium channel blocker (CCB), angiotensin converting enzyme inhibitor 
(ACEI) , and alpha blocker (AB) as outcome variables and used age, sex, and 
diagnosis of congestive heart failure (CHF), dyslipidemia (LIP), coronary artery 
disease (CAD) , chronic obstructive pulmonary disease (COPD), benign 
prostatic hypertrophy (BPH), diabetes mellitus (OM), and renal failure (KID) as 
predictor variables. All nine predictor variables were entered into the model 
before backward elimination of variables with significance levels greater than 
0.01. This conservative significance level was chosen because of the large 
number of observations and to compensate for the use of multiple models. 
The logistic regression models appear below. 
Model 1: 
Model 2: 
Model 3: 
Model 4: 
Model 5: 
Dl=CHF LIP BPH CAD COPD OM KID Age Sex 
BB*= LIP BPH CAD COPD OM KID Age Sex 
CCB=CHF LIP BPH CAD COPD OM KID Age Sex 
ACEl=CHF LIP BPH CAD COPD OM KID Age Sex 
AB*= LIP BPH CAD COPD OM KID Age Sex 
*The beta blocker and alpha blocker models failed to converge. CHF was 
eliminated due to the small numbers of observations in these two models. 
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RESULTS 
The results of univariate, bivariate, and multivariate analyses performed 
using SAS were manually transferred into Microsoft Excel for additional 
calculations and display. These results are summarized in tabular form in the 
body of the text. 
Univariate Analyses 
A total of 32,322 cases met the definition of prevalent hypertension. Of 
those, 4,871 met the definition of incident, uncomplicated hypertension. Of the 
4,871 cases with incident, uncomplicated hypertension, 2,405 had no relevant 
comorbid ities. 
The frequencies and proportions of cases with demographic 
characteristics and relevant comorbidities within the prevalent cases of 
hypertension and the incident, uncomplicated cases of hypertension appear in 
Table 2. Frequencies and proportions of individuals dispensed specific drug 
classes appear in Table 3. 
Of the cases with no relevant comorbidities (Table 4) 58.8% did not fill a 
prescription for antihypertensive pharmacotherapy. Of those filling a 
prescription for antihypertensive pharmacotherapy, almost two thirds were 
treated with one class of therapy alone. Less than one fourth received either a 
diuretic or a beta-blocker as the lone therapeutic class. Over 40% received 
another lone therapeutic class. Diuretics and beta-blockers were each 
prescribed as the first class in therapy almost 20% of the time. Calcium 
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channel blockers and ACE Inhibitors were each prescribed as the first class in 
therapy approximately 30% of the time. Alpha-blockers were prescribed as 
the first class in therapy less than 2% of the time. 
The order of therapeutic class in the treatment regimens is displayed in 
Table 5. Among cases with any comorbidies, the first class in the regimen 
was most frequently a calcium channel blocker (32%) followed by ACE 
inhibitors (29%), diuretics (18%), beta blockers (17%), and alpha blockers 
(3%). The second class in the regimen was most frequently an ACE inhibitor 
(30%) followed by calcium channel blockers and diuretics (each at 25%) , beta 
blockers (19%), and alpha blockers (2%) . Diuretics were the most commonly 
prescribed third line agents (32%) followed by ACE inhibitors and calcium 
channel blockers (each at 26%), beta blockers (11 %), and alpha blockers 
(5%) . Fourth line therapy occurred very infrequently. 
Among cases with no comorbidities, first line therapies were most 
frequently calcium channel blockers (31%), followed by ACE inhibitors (29%) , 
diuretics and beta blockers (each at 19%), and alpha blockers (2%). Second 
line therapy was most commonly an ACE inhibitor (28%), followed by calcium 
channel blockers (27%), diuretics (26%), beta blockers (18%), and alpha 
blockers (2%). Third line therapy was most commonly an ACE inhibitor or 
diuretic (each at 29%), followed by calcium channel blockers (26%), beta 
blockers (10%), and alpha blockers (6%). 
In benign prostatic hypertrophy, alpha blockers were prescribed as first 
line therapy in 23% of cases but ranked only third behind calcium channel 
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blockers and ACE inhibitors (each at 26%). Beta blockers were first line 
therapy in 13% of cases followed by diuretics (12%). Second, third , and fourth 
line therapies were infrequent. 
In chronic obstructive pulmonary disease, calcium channel blockers 
were the class most frequently prescribed as first line therapy (32%) followed 
by ACE inhibitors (30%) , diuretics (22%), beta blockers (10%), and alpha 
blockers (5%). As second line therapy ACE inhibitors were most frequently 
prescribed (35%) followed by calcium channel blockers (29%), diuretics (19%), 
beta blockers (14%), and alpha blockers (4%). Third and fourth line therapies 
were infrequent. 
Congestive heart failure was an infrequent comorbidity. Diuretics were 
used most commonly as first line therapy (55%) followed by ACE inhibitors 
(32%) and calcium channel blockers (14%). 
In coronary artery disease, calcium channel blockers were the class 
most frequently prescribed as first line therapy (42%) followed by beta 
blockers (26%), ACE inhibitors (21%), diuretics (9%), and alpha blockers (2%). 
Second line therapy was most frequently a beta blocker (42%) followed by 
calcium channel blockers (35%) and ACE inhibitors (23%). Third and fourth 
line therapies were infrequent. 
In dyslipidemia, calcium channel blockers were the most frequently 
prescribed first line therapy (33%) followed by ACE inhibitors (30%), diuretics 
(18%), beta blockers (15%), and alpha blockers (4%). ACE inhibitors were the 
most commonly prescribed second line therapy (32%) followed by diuretics 
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(23%), calcium channel blockers and beta blockers (each at 22%), and alpha 
blockers (2%). Third line therapy was most frequently a calcium channel 
blocker (34%) followed by diuretics (31 %), ACE inhibitors (20%), beta blockers 
(9%). and alpha blockers (6%). 
In diabetes mellitus ACE inhibitors were the most frequently prescribed 
first line therapy (46%) followed by calcium channel blockers (32%). diuretics 
(27%), and beta blockers (9%). ACE inhibitors were also most commonly 
prescribed as second line therapy (29%) followed by calcium channel blockers 
(27%). diuretics (24%). beta blockers (15%). and alpha blockers (6%) . 
Renal insufficiency was an infrequent comorbidity. ACE inhibitors were 
most commonly prescribed as first line therapy (40%) followed by diuretics 
(35%), calcium channel blockers (15%), beta blockers and alpha blockers 
(each at 5%) . 
Bivariate Analyses 
Unadjusted Risk Ratios (RR) and 95% Confidence Intervals (Cl) for 
selected bivariate relationships are displayed in Table 6. Statistically 
significant RRs are evident where Cls do not include one. 
Beta-blocker prescribing was positively associated with coronary artery 
disease and negatively associated with chronic obstructive pulmonary 
disease. diabetes mellitus and dyslipidemia. Of the cases with coronary artery 
disease, more than 22% filled a prescription for a beta blocker while those 
without coronary artery disease filled such a prescription less than 9% of the 
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time. These proportions yielded a risk ratio of 2.56 with a 95% confidence 
interval of 1.85-3.56 . Of the cases with chronic obstructive pulmonary disease 
less than 5% filled a prescription for a beta blocker while almost 10% of cases 
without chronic obstructive pulmonary disease filled such a prescription . 
These proportions yielded a RR of 0.47 with Cl 0.31-0.71. Less than 5% of 
patients with diabetes mellitus filled a prescription for a beta blocker while 
almost 10% without diabetes filled such a prescription . These proportions 
yielded a RR of 0.44 with Cl 0.28-0.67. Cases with dyslipidemia filled a 
prescription for a beta blocker 6% of the time while those without dyslipidemia 
filled such a prescription almost 10% of the time. These proportions yielded 
RR 0.62 with Cl 0.50-0.77. 
Coronary artery disease was also positively associated with calcium 
channel blocker prescribing. Cases with coronary artery disease filled 
prescriptions for beta blockers more than 27% of the time while those without 
coronary artery disease filled such prescriptions less than 16% of the time. 
These proportions yielded RR 1.77 with Cl 1.33-2 .36. 
ACE Inhibitor prescribing was positively associated with diabetes 
mellitus and renal failure. ACE inhibitor prescriptions were filled by patients 
with diabetes mellitus in over 20% of cases. Less than 15% of cases without 
diabetes mellitus filled such prescriptions. These proportions yielded RR 1.41 
with Cl 1.17-1.70. ACE inhibitor prescriptions were filled by patients with renal 
failure in more than 28% of cases. Less than16% of cases without renal 
failure filled such a prescription. These proportions yielded RR 1.84 with Cl 
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1.11 -3.04. 
Like beta blockers, diuretics were negatively associated with 
dyslipidemia. Less than 8% of cases with dyslipidemia filled a prescription for 
a diuretic while more than 11 % of those without dyslipidemia filled such a 
prescription. These proportions yielded RR 0.69 with Cl 0.58-0.83. 
Congestive heart failure was positively associated with diuretic 
prescribing . Almost half of the cases with congestive heart failure filled a 
prescription for a diuretic while slightly more than 10% of those without 
congestive heart failure filled such a prescription. These proportions yielded a 
risk ratio (RR) of 4.58 with a 95% confidence interval (Cl) of 2.83-7.42. Benign 
prostatic hypertrophy was positively associated with alpha-blocker prescribing . 
Almost 9% of cases with benign prostatic hypertrophy filled a prescription for 
an alpha blocker while only !% without benign prostatic hypertrophy filled such 
a prescription . The relationships between congestive heart failure and 
diuretics and between alpha blockers and benign prostatic hypertrophy, 
although statistically significant, have questionable validity due to small cell 
sizes. 
Multivariate Analyses 
Multivariate Adjusted Odds Ratios (OR) and Confidence Intervals (Cl) 
from logistic regression analyses appear in Table 8. In the diuretic model , 
congestive heart failure (10.87 OR, 4.70-25.15 Cl) and female gender (0.55 
OR, 0.45-0.66 Cl) were positively associated. 
In the calcium channel blocker model, only coronary artery disease was 
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positively associated (2. 70 OR, 1.88-3 .86 Cl) . In the ACE Inhibitor model both 
congestive heart failure (5.88 OR, 2.57-13.43 Cl) and diabetes mellitus (1 .73 
RR, 1.38-2.16) were positively associated. 
The beta blocker and alpha blocker models failed to converge with all 
nine variables entered initially. Because of the small numbers of congestive 
heart failure cases (23) this variable was eliminated from the beta blocker and 
alpha blocker models. Chronic obstructive pulmonary disease (0.50 OR, 0.33-
0.75 Cl) , diabetes mellitus (0.56 OR, 0.38-0.82 Cl), and male gender (0.64 
OR, 0.52-0.78 Cl) were negatively associated with beta blocker prescribing 
while coronary artery disease was positively associated (4 .39 OR, 2.93-6.56 
Cl) . Benign prostatic hypertrophy (6.02 OR, 3.50-10.36 Cl), older age (0 .39 
OR, 0.20-0.75 Cl), and male gender (2.33 OR, 1.26-4.30 Cl) were positively 
associated with alpha blocker prescribing . 
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DISCUSSION 
This section will start with a discussion of the hypotheses and 
systematically progress from review and comments on the results of the 
specific analyses, through explanations of findings consistent with, and 
findings seemingly inconsistent with , predicted directional relationships. 
Limitations and practical applications will round out the discussion. 
Recommendations will be made regard ing future measurement efforts and 
opportunities for improvement in antihypertensive class selection will be 
identified. 
Predictions were based on the assumption that preferred agents would 
be associated with positive risk factors and less preferred agents would be 
associated with negative risk factors in confirmatory bivariate analyses. The 
positive risk factors should have Risk Ratios greater than one. The negative 
risk factors should have Risk Ratios less than one. The confidence intervals 
for these measures of association should not include one. Significant positive 
relationships should be observed for the following: ACE inhibitors and diuretics 
in congestive heart failure , ACE inhibitors in diabetes mellitus and renal failure , 
beta-blockers and CCBs in coronary artery disease, and alpha-blockers in 
benign prostatic hypertrophy. Significant negative relationships should exist 
for the following: beta-blockers in chronic obstructive pulmonary disease, 
congestive heart failure, dyslipidemia, and diabetes mellitus, CCBs in 
congestive heart failure, and diuretics in dyslipidemia. 
Since beta-blockers and diuretics are preferred for uncomplicated 
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hypertension we should observe a higher proportion of prescribing of these 
agents than CCBs and ACE Inhibitors in cases without relevant comorbidities. 
Predicted significant positive relationships were observed for diuretic 
and ACE inhibitor prescribing in congestive heart failure , beta-blocker and 
CCB prescribing in coronary artery disease, and ACE inhibitor prescribing in 
diabetes mellitus and renal failure. Predicted significant negative relationships 
were observed for beta-blocker prescribing in diabetes mellitus, chronic 
obstructive pulmonary disease, and dyslipidemia. Alpha blockers were 
positively associated with benign prostatic hypertrophy but in both the bivariate 
and logistic regression models the validity of this finding is questionable due to 
small numbers of observations. ACE Inhibitors and diuretics were found to be 
positively associated with congestive heart failure in the logistic regression 
model but not in the bivariate analyses. 
Predicted negative relationships that were not observed include beta-
blocker and CCB prescribing in congestive heart failure. The absence of the 
predicted observations in congestive heart failure may be partially due to the 
availability of new drugs in these classes that are potentially beneficial in this 
disease. In addition, there were few observations in these comorbidities such 
that interpretation of findings within these conditions is difficult. 
In the cases with no relevant comorbidities, treated with 
pharmacotherapy, only one quarter were treated with diuretics or beta-
blockers as the lone class of therapy. Other lone classes of therapy were 
prescribed in 40% of these cases. When looking at first class in the 
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therapeutic regimen, CCBs and ACE Inhibitors account for 60% while diuretics 
and beta blockers account for only 40%. Adherence to guidelines would have 
been demonstrated by greater prescribing of the preferred classes than the 
unpreferred classes. 
There were a number of interesting findings from the order of 
therapeutic class data. Calcium channel blockers and ACE inhibitors appear 
to be preferred over diuretics and beta blockers as first line therapy. That 
preference does not appear to depend greatly upon the presence of 
comorbidities. The cases without relevant comorbidities do receive beta 
blockers and diuretics more frequently than the cases with comorbidities 
however the difference is very small (1-2%) . Diuretics are used in increasing 
proportions as the number of classes in the regimen increases. This is true for 
both cases with and cases without comorbidities. Alpha blockers are 
infrequently prescribed and appear to have a significant role only in first line 
therapy for men with benign prostatic hypertrophy. Even in that group, ACE 
inhibitors and calcium channel blockers are prescribed more frequently than 
alpha blockers. Beta blockers appear less frequently as first line therapy in 
chronic obstructive pulmonary disease and diabetes mellitus than in cases 
without comorbidities. ACE inhibitors seem to be preferred in renal 
insufficiency and diabetes mellitus. 
Limitations 
This measurement model was able to confirm the vast majority of the 
predicted associations. However, potential applications of these results must 
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be weighed against important methodological and theoretical limitations. 
The use of administrative claims data is advantageous because they 
are relatively inexpensive and unobtrusive to obtain. However, an important 
limitation of using the automated health plan databases for research is the lack 
of information on potential confounders. In prescribing for hypertension these 
potential confounders include: race, patient preference, and history of previous 
therapeutic trials. In this study the effect of history of previous therapeutic 
trials was addressed by creating the ideal group of incident, uncomplicated 
cases of hypertension. Race and patient preferences were not accessible in 
this data base. 
Another potential limitation stems from the reliance on dispensing data 
for attribution of prescribing practices. Prescribing could have occurred but if 
the patients did not fill the prescriptions then the prescribing was not counted. 
In the present study, 58% of incident, uncomplicated cases with no relevant 
comorbidities did not fill any prescriptions for antihypertensive therapy. It is 
not known how many of these had prescriptions given and not filled or 
prescriptions not given. It is also important to recall that not all hypertension 
needs to be treated with pharmacotherapy. A trial of lifestyle modification is 
suggested , prior to instituting pharmacotherapy. This study dealt with this 
potential limitation by focusing primarily on the patients who used 
pharmacotherapy. There should only be a problem in interpreting relative 
prescribing of classes if patients were less likely to fill prescriptions for some 
classes compared to others. This question is beyond the scope of this 
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investigation. 
Another potential limitation has to do with the generalizability of the 
findings to other populations . Hawaii is different from other states in its 
relative geographic isolation and in the racial and ethnic composition of its 
population. These differences should not influence prescribing practices since 
the same risks and benefits apply to the different races and ethnic groups. 
There may however, be a cultural difference in the filling of prescribed 
therapies. If Hawaiians are less likely to fill prescriptions than Americans in 
other states then the magnitudes of proportions would be lower in this study 
than if studied in the continental United States. The relative measures of 
prescribing should not be influenced by such a cultural difference however. 
Future studies should attempt to measure these effects in other states and in 
other practice and payer models. 
Another potential limitation of this study stems from the use of multiple 
tests and comparisons. This strategy can lead to the identification of spurious 
relationships. These finding should be confirmed in an independent sample. 
It is also worth noting that the alpha blocker and beta blocker logistic 
regression models did not converge until congestive heart failure was 
removed. The decision to remove congestive heart failure from these models 
was based upon the small number of cases with congestive heart failure. This 
is not surprising given that hypertension is a major risk factor for congestive 
heart failure and there should be very little congestive heart failure in a 
population with incident hypertension. Since the calcium channel blocker, 
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ACE inhibitor, and diuretic models did converge with congestive heart failure 
included, this condition was not removed from these models. It was 
particularly important to look at congestive heart failure in the diuretic and ACE 
inhibitor models since this condition is considered a compelling indication for 
the use of these classes of therapy. 
Coded claims can introduce a potential systematic bias in classification 
of comorbidities and drug prescribing . The use of a diagnostic code can be 
made in error and the filling of a prescription can be made in error. By 
insisting on at least two codes for the definition of comorbidities this study 
should have reduced the probability of falsely including cases with the relevant 
comorbidities. By accepting any dispensing of an antihypertensive agent as 
defining the prescribing this study could have falsely identified some class 
prescribing . Future investigations should explore the use of other drug 
prescribing definitions. 
Measurement Issues 
The measurement strategy used in this study was sufficient to 
demonstrate expected relationships among comorbidities and antihypertensive 
classes. Subsets of comorbidities should have more specificity and therefore 
might show larger effect sizes. Future studies should explore the use of more 
specific subsets (e.g. left heart failure , diabetic nephropathy) in a larger 
population (e.g. prevalent cases of hypertension). A structural model could 
incorporate known causal relationships among diseases, demographic and 
therapeutic variables. It might also be useful to look at specialist-generalist 
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comparisons and high volume provider-low volume provider comparisons to 
further validate the measures. 
Practical Applications 
The study examined the association between population-based, plan 
level, antihypertensive prescribing and comorbidities. Compelling indications 
appear to influence prescribing as do conditions for which there may be 
favorable or unfavorable effects of certain classes of agents. It can also be 
safely stated that diuretics and beta-blockers are not treated as preferred 
agents in uncomplicated hypertension as recommended . 
Opportunities For Improvement in Prescribing 
Opportunities for improvement in prescribing can be classified as 
problems of underutilization or overutilization. Since the JNC continues to 
recommend diuretic and beta-blockers as first line agents for uncomplicated 
hypertension we need to look at the relative utilization of these agents 
compared to other classes. These preferred classes rank third and fourth 
behind CCBs and ACE inhibitors. This can be interpreted as underutilization 
of these preferred classes or overutilization of the more popular but less 
preferred (according to evidence/guidelines) classes for the treatment of 
uncomplicated hypertension. The second area to look at relates to what the 
JNC is now calling compelling indications. These compelling indications are 
based upon randomized controlled clinical trials and were the source of many 
of the predicted relationships in this study. These compelling indications 
include: ACE inhibitors for diabetic nephropathy, ACE inhibitors and diuretics 
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for heart failure, and beta-blockers for post myocardial infarction. The 
numbers of observations within these comorbidity sets was too low for 
meaningful quantitative conclusions. These conditions are expected to be 
uncommon in incident cases of uncomplicated hypertension. A future study 
should attempt to quantify these relationships in prevalent cases of 
hypertension where these important comorbidities have been demonstrated to 
be more prevalent (Table 2). 
Conclusions 
Administrative claims data can be successfully used to measure 
prescribing practices in hypertension. Comorbidities influence prescribing in 
hypertension as outlined in Joint National Commission guidelines. However, 
diuretics and beta blockers are not preferred over calcium channel blockers 
and angiotensin converting enzyme inhibitors as first line therapy in 
uncomplicated hypertension, despite the significant evidence base that 
supports this practice. 
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Table 1. ICD-9 CM• code sets for operational definitions of prevalent cases of 
hypertension and relevant comorbidities: broad definitions 
Hypertension 
Patients with ICD-9 CM codes for hypertension: 401 .x, 402.xx, 403.xx, 404.xx, and 
405.xx 
Coronary Artery Disease 
Patients with ICD-9 CM codes for Myocardial Infarction, lschemic Heart Disease, 
Angina, or Coronary Atherosclerosis: 410.xx, 411 .xx, 412, 413.x, 414, 414.0, 414.8, 
and 414.9 
Congestive Heart Failure 
Patients with ICD-9 CM codes for Heart Failure: 428.x, 402.x1 , 404.x1 , and 404.x3 
Diabetes Mellitus 
Patients with ICD-9 CM codes for Diabetes Mellitus: 250.xx 
Chronic Obstructive Pulmonary Disease 
Patients with ICD-9 CM codes for Asthma, Chronic Bronchitis, Emphysema, 
Bronchitis Not Specified as Acute or Chronic, and Chronic Airway Obstruction Not 
Elsewhere Classified: 490, 491 .xx, 492.x, 493.xx, and 496. 
Benign Prostatic Hypertrophy 
Patients with ICD-9 CM code for BPH: 600 
Dyslipidemias 
Patients with ICD-9 CM codes for Disorders of Lipoid Metabolism or Hyperlipidemias: 
272.x 
Kidney Disease 
Patients with ICD-9 CM codes for Renal Failure, Nephrotic or Nephritic Disorders, 
Hypertensive Renal Disease, or Diabetic Nephropathy: 581 .x, 582.xx, 583.xx, 584.x, 
585, 586, 587, 403.xx, 404.xx, and 250.4x 
* HCFA (1994) 
39 
Table 1. (Cont.) ICD-9 CM• code sets for operational definitions of prevalent cases of 
hypertension and relevant comorbidities: specific subsets 
Hypertension. Uncomplicated Essential (Specific Subset of Hypertension) 
Patients with ICD-9 CM codes for Essential , Benign Essential , and Unspecified 
Essential Hypertension: 401 , 401 . 1, and 401 .9 without ICD-9 CM codes for Malignant 
Hypertension, Hypertensive Heart Disease, Hypertensive Renal Disease, or 
Secondary Hypertension: 401 .0, 402.xx, 403.xx, 404.xx, and 405.xx 
Hypertension, Uncomplicated Essential Incident Cases (Specific Subset of 
Hypertension) 
Patients classified as Uncomplicated Essential Hypertension in whom the first 
appearance of the ICD-9 CM code for Hypertension is preceded by a one year period 
free of anti-hypertensive pharmacotherapy. 
Post Myocardial Infarction (Specific Subset of Coronary Artery Disease) 
Patients with ICD-9 CM codes for Myocardial Infarction, Post Myocardial Infarction 
Syndrome, or Old Myocardial Infarction: 41 O.xx, 411 .0, and 412 
Left Heart Failure (Specific Subset of CHFl 
Patients with ICD-9 CM codes for Left Heart Failure: 428.1 
Hypertensive Heart Disease with Congestive Heart Failure (Specific Subset of CHFl 
Patients with ICD-9 CM codes for Hypertensive Heart Disease with CHF: 402.x1, 
404.x1 and 404.x3 
Asthma (Specific Subset of COPD) 
Patients with ICD-9 CM codes specific to Asthma: 493.xx 
* HCFA (1994) 
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Table 1. (Cont.) ICD-9 CM• code sets for operational definitions of prevalent cases 
of hypertension and relevant comorbidities: specific subsets 
Type 1 Diabetes Mellitus (Specific Subset of OM) 
Patients with ICD-9 CM codes for Diabetes Mellitus Type 1: 250.x1 
Hypertensive Renal Disease (Specific Subset Kidney Disease) 
Patients with ICD-9 CM codes for Hypertensive Renal Disease: 403.xx and 404.xx 
Diabetic Nephropathy 1 (Specific Subset of Kidney Disease and DMl 
Patients with ICD-9 CM codes for Diabetes Mellitus with Renal Manifestation or 
Diabetes Mellitus and Chronic or Unspecified Renal Failure: 250.4x, 250.xx and (585 
or 586) 
Diabetic Nephropathy 2 (More Specific Subset of Kidney Disease and DMU 
Patients with ICD-9 CM codes for Diabetes Mellitus with Renal Manifestations: 250.4x 
Other Renal Disease (Specific Subset of Kidney Disease) 
Patients with ICD-9 CM codes for non-hypertensive and non-diabetic renal diseases: 
581.xx, 582.xx, 583.xx, 584.x, 585, and 586, 587 
• HCFA (1994) 
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Table 2. Frequencies and (proportions) of demographics & relevant comorbidities in 
prevalent cases of hypertension and incident. uncomplicated cases of hypertension 
Prevalent Incident. 
Hypertension Uncomplicated 
Hypertension 
N = 32,322 N =4,871 
Older Age (>64) 2548 (7.9) 237 (4.9) 
Female 15,422 (47.8) 2343 (48.1) 
Chronic Obstructive Pulmonary 3695 (11.4) 514 (10.6) 
Disease 
Asthma 1991 (6.2) 269 (5.5) 
Benign Prostatic Hypertrophy 2808 (8.7) 282 (5.8) 
-'- ...s ...':.. ..o:_ Coronary Artery Disease 2934 (9.1) 141 (2.9) 
Post Myocardial Infarction 501 (1 .6) 25 (0.5) 
Dyslipidemia 15442 (47.8) 1834 (37.7) 
Congestive Heart Failure 915 (2.8) 23 (0.5) 
Left Heart Failure 91 (0.3) 2 (0) 
Hypertensive Heart Failure 130 (0.4) 0 (0) 
Diabetes Mellitus 5936 (18.4) 515(10.6) 
Type 1 Diabetes Mellitus 651 (2.0) 34 (0.7) 
Renal Failure 1029 (3.2) 41 (0.8) 
Diabetic Nephropathy (Def 1) 225 (0.7) 3 (0.1) 
Diabetic Nephropathy (Def 2) 398 (1 .2) 8 (0.2) 
Hypertensive Renal Failure 363 (1 .1) 0 (0) 
Other Renal Failure 816 (2.5) 38 (0.8) 
Diabetic Nephropathy definitions in Table 1. 
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Table 3. Frequencies and (proportions) of patients dispensed drug classes in 
prevalent cases of hypertension and in incident, uncomplicated cases of hypertension 
Drug Prevalent 
Class Hypertension 
(N = 32,322) 
Diuretic 8346 (25.8) 
Beta-Blocker 6834 (21 .1) 
CCB 13248 (41 .0) 
ACEI 10683 (33.1) 
Alpha-Blocker 1430 (6.7) 
ARB 1430 (4.4) 
Sympatholy1ic 1447 (4.5) 
Vasodilator 381 (1 .2) 
CCB = Calcium Channel Blocker 
ACEI = Angiotensin Converting Enzyme Inhibitor 
ARB= Angiotensin II Receptor Blocker 
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Incident, 
Uncomplicated 
Hypertension 
J_N = 4,87!2_ 
514 (10.6) 
446 (9.2) 
787(16.2) 
755 (15.5) 
74 (1 .5) 
143 (2.9) 
51 (1 .0) 
3 (0.1) 
Table 4. Antihypertensive drug classes dispensed in incident, uncomplicated cases 
with no relevant comorbidities• 
Frequencies Frequencies and 
and (Proportions) of 
(Proportions) those Dispensed 
of Total Cases Antihypertensive 
(N=2405) Drug(s) (N=991) •• 
No Drug_ 1414 58.81 0 Ol 
Diuretic 272j 11 .31 272 27.4 
Beta-blocker 246 10.2 246 24.8 
CCB 390 16.2 390 39.4 
ACE Inhibitor 368 15.3 368J:371 
A!e_ha-blocker 68J:2.![ 68J:6~ 
Diuretic alone 92J:3.![ 9iI9 :t_ 
Beta-blocker 129 (5.4) 129 (13.0) 
alone 
CCB alone 21619~ 216J:21 .![ 
ACE Inhibitor 181 (7.5) 181 (18.3) 
alone 
Alpha-blocker 9 (0.4) 9 (0.9) 
alone 
Frequencies and (Proportions) 
as First Class in Therapy 
J_N=102"Q •• 
Diuretic 199l19.4[ 
Beta-blocker 199l19.4[ 
CCB 319131.1}_ 
ACE Inhibitor 294_(28.6}_ 
AIQha-blocker 16_i1 .6}_ 
• Cases with incident, uncomplicated hypertension without any of the following 
comorbidities: coronary artery disease, congestive heart failure, chronic obstructive 
pulmonary disease, dyslipidemia, diabetes mellitus, renal failure, and benign prostatic 
hypertrophy. 
•• N's don't match due to 36 ties for first class in therapy. 
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Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated 
cases of hypertension 
Order Diuretic 
Freg_ % 
Any_ 1 371 18 
2 115 25 
3 24 32 
4 4 44 
None 1 199 19 
2 61 26 
3 9 29 
4 3 60 
BPH 1 12 12 
2 7 32 
3 1 33 
4 0 0 
Any = Any Comorbidities 
None = No Comorbidities 
Beta 
Block 
Freg_ % 
347 17 
88 19 
8 11 
3 33 
199 19 
43 18 
3 10 
1 20 
13 13 
5 23 
0 0 
0 0 
BPH = Benign Prostatic Hypertrophy 
CCB = Calcium Channel Blocker 
CCB 
Freg_ % 
648 32 
117 25 
20 26 
2 22 
318 31 
63 27 
8 26 
1 20 
27 26 
5 23 
2 67 
0 0 
ACEI = Angiotensin Converting Enzyme Inhibitor 
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ACEI Alpha 
Block 
Freg_ % Freg_ % 
595 29 61 3 
140 30 9 2 
20 26 4 5 
0 0 0 0 
294 29 16 2 
65 28 4 2 
9 29 2 6 
0 0 0 0 
27 26 24 23 
3 14 2 9 
0 0 0 0 
0 0 0 0 
Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated 
cases of hypertension 
Orde Diuretic Beta CCB 
r Block 
Fr~ % Fr~ % Fr~ % 
COP 1 43 22 20 10 63 32 
D 
2 10 19 7 14 15 29 
3 3 30 0 0 1 10 
4 0 0 0 0 1 100 
CHF 1 12 55 0 0 3 14 
2 0 0 0 0 2 33 
3 1 50 0 0 0 0 
4 0 0 0 0 0 0 
CAD 1 8 9 24 26 38 42 
2 0 0 11 42 9 35 
3 3 50 0 0 0 0 
4 0 0 1 100 0 0 
COPD = Chronic Obstructive Pulmonary Disease 
CHF =Congestive Heart Failure 
CAD = Coronary Artery Disease 
CCB = Calcium Channel Blocker 
ACE/ = Angiotensin Converting Enzyme Inhibitor 
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ACE/ Alpha 
Block 
Fr~ % Fr~ % 
59 30 10 5 
18 35 2 4 
5 50 1 10 
0 0 0 0 
7 32 0 0 
4 67 0 0 
1 50 0 0 
0 0 0 0 
19 21 2 2 
6 23 0 0 
3 50 0 0 
0 0 0 0 
Table 5: Order of therapeutic class in treatment regimens in incident uncomplicated 
cases of hypertension 
Order Diureti Beta CCB ACEI Alpha 
c Block Block 
Freg_ % Freg_ % Fregj % Freg_ % Freg_ % 
LIP 1 128 18 108 15 235 33 212 30 31 4 
2 38 23 36 22 37 22 53 32 3 2 
3 11 31 3 9 12 34 7 20 2 6 
4 1 33 1 33 1 33 0 0 0 0 
DM 1 27 12 20 9 70 32 101 46 1 0 
2 13 24 8 15 15 27 16 29 3 6 
3 6 67 2 22 0 0 1 11 0 0 
4 0 0 1 100 0 0 0 0 0 0 
KID 1 7 35 1 5 3 15 8 40 1 5 
2 1 13 0 0 3 38 4 50 0 0 
3 0 0 0 0 0 0 1 100 0 0 
4 0 0 0 0 0 0 0 0 0 0 
LIP = Dyslipidemia 
DM = Diabetes Mellitus 
KID =Renal Insufficiency 
CCB = Calcium Channel Blocker 
ACEI = Angiotensin Converting Enzyme Inhibitor 
47 
Table 6. Unadjusted risk ratios and confidence intervals for selected bivariate 
relationships in incident, uncomplicated cases of hypertension 
Congestive Proportion Proportion Risk Confidence 
Heart Failure with Risk without Ratios Intervals 
Factor on Risk Factor on (95%) 
Class Class 
Diuretic 47.37 10.33 4.58 2.83 - 7.42. 
+ 
Coronary 
Artery 
Disease 
Beta-Blocker 22.22 8.67 2.56 1.85 - 3.56. 
CCB 27.69 15.64 1.77 1.33-2.36* 
Diabetes 
Mellitus 
Beta-Blocker 4.16 9.53 0.436 0.28- 0.67. 
ACE Inhibitor 20.60 14.62 1.41 1.17-1 .70* 
Renal Failure 
ACE Inhibitor 28.21 15.36 1.84 1.11 - 3.04 . 
ICOPD ~eta-Blocker 14.51 19.62 lo.47 I 0.31 - 0.71 • 
Dyslipidemia 
Diuretic 7.59 11 .06 0.69 0.58- 0.83. 
Beta-Blocker 6.07 9.81 0.62 0.50- 0.77. 
Benign 
Prostatic 
f:!yQ_ertr~ 
Alpha- 8.90 1.05 8.51 5.33 - 13.58 • 
Blocker + 
CCB = Calcium Channel Blocker 
ACE = Angiotensin Converting Enzyme 
COPD = Chronic Obstructive Pulmonary Disease 
• = Confidence Interval Does Not Include 1 
+ = Questionable Validity Due to Small Number of Observations 
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Table 7. Adjusted odds ratios and confidence intervals from logistic regression 
analyses in incident, uncomplicated cases of hypertension 
Diuretic Model 
Dl=COPD BPH CAD LIP CHF OM KID Age Sex 
Variables Odds Ratios Confidence Intervals 
J_Wald, 95°/~ 
CHF 10.87 4.70- 25.15 
Male 0.55 0.45 - 0.66 
Calcium Channel Blocker Model 
CCB=COPD BPH CAD LIP CHF OM KID Age Sex 
Variables 
CAD 
ACE Inhibitor Model 
Odds Ratios 
2.70 
Confidence Intervals 
(Wald, 95%) 
1.88 - 3.86 
ACEl=COPD BPH CAD LIP CHF OM KID Age Sex 
Odds Ratios Confidence Interval 
Variables (Wald, 95%) 
CHF 5.88 2.57 - 13.43 
OM 1.73 1.38-2.16 
COPD = Chronic Obstructive Pulmonary Disease 
CAD= Coronary Artery Disease CHF =Congestive Heart Failure 
BPH =Benign Prostatic Hypertrophy OM= Diabetes Mellitus 
KID= Renal Failure LIP= Dyslipidemia 
Older Age = Age >64 
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Table 7. Adjusted odds ratios and confidence intervals from logistic regression 
analyses in incident, uncomplicated cases of hypertension 
Beta Blocker Model 
BB=COPD BPH CAD LIP OM KID Age Sex 
Odds Ratios Confidence Intervals 
Variables (Wald, 95%) 
COPD 0.50 0.33- 0.75 
CAD 4.39 2.93-6.56 
OM 0.56 0.38-0.82 
Male 0.64 0.52 - 0.78 
Alpha-Blocker Model 
AB=COPD BPH CAD LIP OM KID Age Sex 
Odds Ratios Confidence Intervals 
Variables (Wald, 95%) 
BPH 6.02 3.50 -10.36 
A_g_e 0.39 0.20-0 .75 
Male 2.33 1.26-4.30 
COPD = Chronic Obstructive Pulmonary Disease 
CAD= Coronary Artery Disease CHF =Congestive Heart Failure 
BPH =Benign Prostatic Hypertrophy OM= Diabetes Mellitus 
KID= Renal Failure LIP= Dyslipidemia 
Older Age = Age >64 
• CHF eliminated from beta blocker and alpha blocker models due to small numbers 
of observations 
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Appendix A: Alternatives for Operational Definitions of Prevalent Cases 
Various operational definitions for prevalent cases were considered and 
tested for their effects on potential sample size. These operational definitions 
varied in two different dimensions: the number of required occurrences of the 
target ICD-9 CM codes and the duration of the interval during which codes 
must appear. 
The first dimension varied from one code in the time interval, to two 
codes, to three codes. The second dimension varied in the duration of the 
time interval from index diagnosis date plus one year, to index diagnosis date 
plus two years, to the entire three calendar years. The index diagnosis date 
was the date on which the first diagnosis code from the respective comorbidity 
set appeared in the claims history. 
The table (below) shows the frequencies and proportions of 
observations, in a 50% random sample, meeting the various comorbidity 
definitions for the number of codes required and duration of the interval. 
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Table. Operational Definitions of Prevalent Cases of Hypertension and 
Relevant Comorbities, according to number of codes required and time 
interval for observing the codes, with frequencies and (proportions) reported . 
N=19,707 from a 50% random sample 
Prevalent Cases of 3 Codes (GE) 2 Codes (GE) 1 Codes (GE) 
H_ye_ertension 
Index diagnosis+ 1_yr 11,811J:59.9} 14,916175.fl 19, 70711 ocIT 
Index di'!ll_nosis + 2 _yr 13,488 _{_68.1_2_ 15,912 (80.D_ 19,707_{_100) 
1994-1996 13,839 J,_70.21 16 , 080_{_81.~ 19, 707 _{_1 OQ2_ 
Incident, 3 Codes (GE) 2 codes (GE) 1 Codes (GE) 
Uncomplicated Cases 
of H...1'2_ertension 
Index di'!ll_nosis + 1 _1'.!: 9,263 _{_47.QL 12,016 _{_61.QL 16,535 _{_83 .9) 
Index di'!ll_nosis + 2 E 10,648 J:54.<IT 12,864165.~ 16 ,535183 .~ 
1994 - 1996 10,945155.!& 13,011]_66.Qi 16,535183.91 
BPH 2 Codes (GE 1 Codes (GE 
Index dia nosis + 1 r 1,123 5.7 2,751 14.0 
Index dia nosis + 2 r 1,484 7.5 2,751 14.0 
1994 - 1996 1,540 7.8 2,751 14.0 
LIP 3 Codes_{_GEl 2 Codes_{_G~ 1 Codes1GE) 
Index di'!ll_nosis + 1_1'.!: 5,596 _{_28.'!2._ 7,898 _{_40 .1_2_ 11 , 531_{_58 .~ 
Index di'!ll_nosis + 2 _yr 6,860134.l[ 8,739144 3I 11,531~8.~ 
1994 - 1996 7,143_{_36.~ 8,892 _{_451_2_ 11,531 (58.5) 
BPH 
LIP 
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Table. Operational Definitions of Prevalent Cases of Hypertension and 
Relevant Comorbities, according to number of codes required and time 
interval for observing the codes, with frequencies and (proportions) reported. 
N=19,707 from a 50% random sample 
CAD 
Index dia nosis + 1 
Index dia nosis + 2 
1994 - 1996 
Ml 
1994 - 1996 
CHF 
Index Dia nosis + 1 
Index Dia nosis + 2 
1994 - 1996 
LHF 
1994 - 1996 
HHF 
1994 - 1996 
CAD = Coron'!!Y_ Art~ Disease 
Ml = Post M__y_ocardial Infarction 
CHF = Co~estive Heart Failure 
LHF = Left Heart Failure 
HHF = H_i'j'.l_ertensive Heart Failure 
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Table. Operational Definitions of Prevalent Cases of Hypertension and 
Relevant Comorbities, according to number of codes required and time 
interval for observing the codes, with frequencies and (proportions) reported . 
N=19,707 from a 50% random sample 
COPD 1 Codes GE 
Index Dia nosis + 1 r 3,884 19.7 
Index Dia nosis + 2 r 3,884 19.7 
1994 - 1996 3,884 19.7 
ASTH 
Index Dia nosis + 1 r 
Index Dia nosis + 2 r 
1994 - 1996 
DM 
Index Dia nosis + 1 r 
Index Dia nosis + 2 r 
1994 - 1996 
DMT1 
Index Dia nosis + 1 r 
Index Dia nosis + 2 r 
1994 - 1996 
COPD = Chronic Obstructive Pulmona_!l'_ Disease 
ASTH =Asthma 
DM = Diabetes Mellitus 
DMT1 = Diabetes Mellitus TyJJ_e 1 
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Table_ Operational Definitions of Prevalent Cases of Hypertension and 
Relevant Comorbities, according to number of codes requ ired and time 
interval for observing the codes, with frequencies and (proportions) reported _ 
N=19,707 from a 50% random sample 
KID 
1994 - 1996 
HRF 
1994 - 1996 
ORF 
Index Dia nosis + 1 
Index Dia nosis + 2 
1994 - 1996 
KID 
DMNe h1 
DMNe h2 
HRF 
ORF 
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Appendix B. Abbreviations Of Comorbidity Clusters And Drug Classes 
COPD = Chronic Obstructive Pulmona_!Y Disease 
ASTH =Asthma 
BPH = Benign Prostatic H_l'f)_eJE!asia 
LIP =~~demia 
CAD = Coronan--_ ArtEllY_ Disease 
Ml = Post M_.Y.ocardial Infarction 
CHF = Co~estive Heart Failure 
LHF = Left Heart Failure 
HHF = t:!.w_ertensive Heart Failure 
OM = Diabetes Mellitus 
DMT1 = Diabetes Mellitus T_}IE)_e 1 
KID = Renal Failure 
DMN~h1 = Diabetic N~hrqE_at~Definition IT 
DMNeQh2 = Diabetic N~hr~tt}y{Definition ~ 
HRF = t:!.w_ertensive Renal Failure 
ORF = Other Renal Failure 
DI =Diuretics 
BB = Beta Blockers 
CCB = Calcium Channel Blockers 
ACEI = A~otensin Converti~ En~me Inhibitors 
AB = A.!E_ha Blockers 
ARB = A~otensin Rec~or Blockers 
SY = ~m_Q_atho_Mi_cs 
VD = Vasodilators 
56 
BIBLIOGRAPHY 
Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US 
adult population: results from the Third National Health and Nutrition 
Examination Survey, 1988-1991 . Hypertension 1995; 25: 305-313. 
Donabedian A. Evaluating the quality of medical care. Mil/bank Memorial 
Fund Quarterly 1966; 166-206. 
Drake DF. Managed care: a product of market dynamics. Journal of the 
American Medical Association 1997; 277: 560-563. 
Glauber HS and Brown JB. Use of health maintenance organization data 
bases to study pharmacy resource usage in diabetes mellitus. Diabetes Care 
1992; 15: 870-876. 
Hawaii Medical Services Association Foundation. Overview of resources for 
research at HMSA. (1995) 
Health Care Financing Administration. International Classification of 
Diseases, g'h Revision. US Department of Health and Human Servives, Public 
Health Service, Health Care Financing Administration (1994) 
Hennekens CH, Albert CM, Godfried SL, Gaziano JM, and Buring JE. 
Adjunctive drug therapy of acute myocardial infarction-evidence from clinical 
trials. New England Journal of Medicine 1996; 335: 1660-1667. 
lezzoni LI. Assessing quality using administrative data. Annals of Internal 
Medicine 1997; 127: 666-674. 
Jencks SF and Wilensky GR. The health care quality initiative. Journal of the 
American Medical Association 1992; 168: 900-903. 
Joint Commission on Accreditation of Healthcare Organizations. Improving 
organizational performance. In: Accreditation manual for home care. (1994) 
JCAHO, Oakbrook Terrace Illinois, p. 162. 
Joint National Committee on Prevention, Detection , Evaluation , and Treatment 
of High Blood Pressure and the National High Blood Pressure Education 
Program Coordinating Committee. The sixth report of the joint national 
committee on prevention, detection, evaluation, and treatment of high blood 
pressure. Archives of Internal Medicine 1997; 157: 2413-2446. 
57 
Joint National Committee on Detection , Evaluation, and Treatment of High 
Blood Pressure. The fifth report of the Joint National Committee on Detection , 
Evaluation, and Treatment of High Blood Pressure (JNC VJ. Archives of 
Internal Medicine 1993; 153: 154-183. 
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and 
treatment. Journal of the American Medical Association 1996; 275: 1571-1576. 
Kaplan NM. Treatment of hypertension: drug therapy. In: Clinical 
Hypertension, 7th ed. 181-263. (1998a) 
Kaplan NM. Treatment of hypertension: drug therapy. In : Clinical 
Hypertension, 5th ed . 191-280. (1994) 
Kaplan NM. Management of Hypertension , 5th Ed. Durant OK: Essential 
Information Systems, 1993. 
Kaplan NM. Gifford RW. Choice of initial therapy for hypertension. Journal of 
the American Medical Association 1996; 275: 1577-1580. 
Kaplan NM. Treatment of hypertension: rationale, guidelines, and goals. In : 
Clinical Hypertension, yth ed. 133-158 (1998b) p. 133. 
Kaplan NM. Hypertension in the population at large. In: Clinical Hypertension , 
yth ed. 1-17. (1998c) 
Kaplan NM. Primary hypertension: natural history, special populations, and 
evaluation. In: Clinical Hypertension , yth ed . 101-132. (1998d) 
Kaplan NM. Treatment of hypertension: nondrug therapy. In: Clinical 
Hypertension, yth ed . 159-179 (1998e) 
Levy DL, Larson, MG, Ramachandran SV, Kannel, WB, Ho KKL. The 
progression from hypertension to congestive heart failure. Journal of the 
American Medical Association 1996; 275: 1557-1562. 
Margolis S, Klag MJ. Hypertension. 1998. The Johns Hopkins White Papers . 
The Johns Hopkins Medical Institutions, Baltimore, Md. 
Melum MM. Total quality outcomes management: a guide to integrating 
outcomes measurement and TQM to improve health care. (1995) 
GOAUQPC, Methuen, MA 
58 
Mehta SS, Wilcox CS, and Schulman KA. Treatment of hypertension in 
patients with comorbidities: results from the study of hypertensive prescribing 
practices (SHyPP). American Journal of Hypertension 1999; 12: 333-40. 
Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced 
dietary sodium on blood pressure: A meta-analysis of randomized controlled 
trials. Journal of the American Medical Association 1996; 275: 1590-1597. 
Moser M. Why are physicians not prescribing diuretics more frequently in the 
management of hypertension? Journal of the American Medical Association 
1998; 1813-1816. 
O'Connor PJ , Rush WA, Pronk NP, and Cherney LM. Identifying diabetes 
mellitus or heart disease among health maintenance organization members: 
sensitivity, specificity, predictive value, and cost of survey and database 
methods. American Journal of Managed Care 1998; 4: 335-342. 
Palmer RH. Process-based measures of quality: the need for detailed clinical 
data in large health care databases. Annals of Internal Medicine 1997; 127: 
733-738. 
President's Advisory Commission on Consumer Protection and Quality in the 
Health Care Industry. Quality first: better health care for all Americans. 1998. 
US Government Printing Office, Washington , DC 
Quam L, Ellis LBM, Venus MA, Clouse J, Taylor CG, and Leatherman S. 
Using claims data for epidemiologic research: the concordance of claims-
based criteria with the medical record and patient survey for identifying a 
hypertensive population. Medical Care 1993; 31: 498-507. 
SAS Institute. SAS Procedures Guide, Version 6, 3rd ed . (1995a) 
SAS Institute. Logistic regression examples: using the SAS system. Version 
6, 151 ed. (1995b) 
Siegel D and Lopez J. Trends in antihypertensive drug use in the United 
States: Do the JNC V recommendations affect prescribing? Journal of the 
American Medical Association 1997; 278: 1745-1779. 
Toscani MR. Moving toward a health management system. In: 
Pharmacoeconomics and outcomes 1997; American College of Clinical 
Pharmacy. p.15-37. 
59 
The Treatment of Mild Hypertension Study Research Group. The treatment of 
mild hypertension: a randomized, placebo-controlled trial of a nutritional-
hygienic regimen along with various drug monotherapies. Archives of lntemal 
Medicine 1991 ; 151 : 1413-1423. 
Woodwell DA. National Ambulatory Medical Care Survey: 1995 Summary 
Advance data from vital and health statistics; no. 286. Hyattsville, Maryland. 
National Center for Health Statistics, 1997. 
60 
